Xtandi is an anti-cancer drug owned by Astellas. It was first authorized for market use on 31st August, 2012. The drug comes in the form of an oral capsule and its active ingredient is enzalutamide.
The generic release of Xtandi is anticipated to occur after 13th August, 2027, following the expiration of the last held drug patent. This makes the Xtandi generic version a future possibility for patients requiring a potentially lower-cost alternative for their treatment.
Xtandi is predominantly used for the treatment of patients with metastatic castration-sensitive prostate cancer and castration-resistant prostate cancer (CRPC). Its active ingredient, enzalutamide, inhibits an important pathway in the development of these conditions, making it effective in managing them.
There are currently 3 patents held for Xtandi, with none having expired so far. The most immenent patent, 'US7709517', with the title 'Diarylhydantoin compounds', is due to expire on 13th of August, 2027. This denotes the anticipated generic release of Xtandi. Below are the details of the patent: